61/297US=1-A / Farmacologia
Krensky AM, Vicenti F, Bennett WM. Imunossupressores, tolerógenos e imunoestimulantes. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman: as bases farmacológicas da terapêutica. 11ª ed. Porto Alegre: AMGH, 2010. p. 1265-89. ISBN 85-6330801-6.

SISTEMA IMUNOLOGICO; AGENTES IMUNOSSUPRESSORES; ESTEROIDES ADRENOCORTICAIS; INIBIDORES DA CALCINEURINA; AGENTES ANTIPROLIFERATIVOS; AGENTES ANTIMETABOLICOS; SIROLIMUS; EVEROLIMUS; AZATIOPRINA; MICOFENOLATO-MOFETILA; FTY720; ANTICORPOS POLICLONAIS; ANTICORPOS MONOCLONAIS; IMUNOESTIMULACAO; IMUNOTERAPIA PARA ESCLEROSE MULTIPLA


62/297US=1-A / Farmacologia
Farwell AP, Braverman LE. Tireóide e fármacos antitireoidianos. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman: as bases farmacológicas da terapêutica. 11ª ed. Porto Alegre: AMGH, 2010. p. 1363-90. ISBN 85-6330801-6.

TIREOIDE; INIBIDORES DA TIREOIDE; FARMACOS ANTIREOIDIANOS; IODETO; IODO RADIOATIVO


63/297US=1-A / Farmacologia
Schimmer BP, Parker KL. Hormônio adrenocorticotrópico; esteróides adrenocorticais e seus análogos sintéticos; inibidores da síntese e das ações dos hormônios adrenocorticais. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman: as bases farmacológicas da terapêutica. 11ª ed. Porto Alegre: AMGH, 2010. p. 1433-57. ISBN 85-6330801-6.

HORMONIO ADRENOCORTICOTROPICO (ACTH); CORTICOTROPINA; ESTEROIDES ADRENOCORTICAIS; CORTICOESTEROIDES; INIBIDORES DOS ESTEROIDES ADRENOCORTICAIS; ANTIGLICOCORTICOIDES


64/297US=1-A / Farmacologia
Davis SN. Insulina, agentes hipoglicemiantes orais e a farmacologia do pâncreas endócrino. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman: as bases farmacológicas da terapêutica. 11ª ed. Porto Alegre: AMGH, 2010. p. 1459-88. ISBN 85-6330801-6.

INSULINA; DIABETES MELITO; INSULINOTERAPIA; AGENTES HIPOGLICEMIANTES ORAIS; SULFONILUREIAS; REPAGLINIDA; NATEGLINIDA; BIGUANIDAS; TIAZOLIDINEDIONAS; INIBIDORES DA X-GLICOSIDASE; GLUCAGON


65/297US=5 / Biol/Mol
Koh MY, Spivak-Kroizman TR, Powis G. HIF-1alfa and cancer therapy. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 15-34. (Recent results in cancer research) ISBN 978-3-540-78280-3.

CANCER; TRATAMENTO; HIF-1; BIOLOGIA MOLECULAR DO HIF-1; REGULACAO DO HIF-1; ONCOGENICOS; HIPOXIA; INIBIDORES DE HIF-1


66/297US=6 / Ortopedia
Taxel P, Mirza FS. Hormonal therapies in breast and prostate cancer: effects on bone and the role of bisphosphonates. In: Bronner F, Farac-Carson MC. Bone and cancer. New York: Springer-Verlag, 2009. p. 205-18. (Topics in bone biology) ISBN 978-1-84882-018-0.

TERAPIAS HORMONAIS; CANCER DE MAMA; CANCER DE PROSTATA; BISFOSFONATOS; INIBIDORES DA AROMATASE; PERDA OSSEA. PREVENCAO; PERDA OSSEA. TRATAMENTO; OSTEOPOROSE


67/297US=7 / Gastro
Folprecht G. Biologicals for colorectal cancer metastases. In: Vauthey JN, Hoff PMG, Audisio RA, Poston GJ. Liver metastases. New York: Springer, 2009. p. 91-7. ISBN 978-1-84628-946-0.

CANCER COLORRETAL; RECEPTORES DE FATOR DE CRESCIMENTO EPIDERMICO (EGFR); TOXICIDADE; INIBIDORES DE TIROSINA-QUINASE; TERAPIA ANTI-ANGIOGENETICA


68/297US=14 / Dermatologia
Geissler EK. Immunosuppression. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 23-43. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8.

CANCER DE PELE; TRANSPLANTE; IMUNOSSUPRESSAO; IMUNOSSUPRESSAO DE TRANSPLANTES. HISTORICO; IMUNOSSUPRESSAO FARMACOLOGICA; INIBIDORES DA CALCINEURINA; ACIDO MICOFENOLICO; INIBIDOR DE MTOR; AZATIOPRINA; CORTICOSTEROIDE; FTY720; OKT3; TIMOGLOBULINA; INTERLEUCINA-2 (IL-2); ALEMTUZUMAB; CAMPATH-1H


69/297US=14 / Dermatologia
Perrett CM, Harwood CA, McGregor JM, Karran P. Carcinogenic mechanisms related to immunosuppressive therapy. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 123-32. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8.

MECANISMOS CANCERIGENOS; TERAPIA IMUNOSSUPRESSORA; CARCINOGENESE; GLUCOCORTICOIDES; CICLOSPORINA; AZATIOPRINA; INIBIDORES DE MTOR


70/297US=15 / Biol/Mol
Stern R. Hyaluronidases in cancer biology. In: ___. Hyaluronan in cancer biology. Amsterdam: Elsevier, 2009. p. 207-20. ISBN 978-0-12-374178-3.

CANCER; HIALURONIDASE; BIOLOGIA DO CANCER; EFEITO WARBURG; INIBIDORES DE HIALURONIDASE; CD44; AGENTES QUIMIOTERAPICOS


71/297US=14 / Dermatologia
Morelon E, Mahe E, Touraine JL. The role of the transplant physician in the management of skin cancers after organ transplantation. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 377-90. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8.

CANCER DE PELE; RESPONSABILIDADE MEDICA; TRANSPLANTE DE ORGAOS; CLINICO DE TRANSPLANTE; IMUNOSSUPRESSAO; INIBIDORES DE MTOR; CANCER DE PELE NAO MELANOMA


72/297US=14 / Urologia
Salonia A, Briganti A, Gallina A, Montorsi F. The utility of PDE5 inhibitors after radical prostatectomy. In: Mulhall JP. Sexual function in the prostate cancer patient. New York: Humana Press, 2009. p. 163-75. ISBN 978-1-60327-554-5.

INIBIDORES DA PDE5 APOS PROSTATECTOMIA RADICAL; DISFUNCAO ERETIL; PROSTATECTOMIA RADICAL; SILDENAFIL; TADALAFIL; VARDENAFIL


73/297US=9 / Quimioterapia
Flora S, Bennicelli C, Battistella A, Bagnasco. Mechanisms of chemoprevention, antimutagenesis, and anticarcinogenesis: an overview. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 57-72. ISBN 978-3-527-32058-5.

MECANISMOS DE QUIMIOPREVENCAO; ANTIMUTAGENESE; ANTICARCINOGENESE; AGENTES QUIMIOPREVENTIVOS; MECANISMOS DE INIBIDORES DE MUTAGENESE; CARCINOGENESE


74/297US=9 / Quimioterapia
Kennedy AR. Protease inhibitors. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 761-7. ISBN 978-3-527-32058-5.

INIBIDORES DE PROTEASE


75/297US=6 / Quimioterapia
Airley R. Classical anticancer agents. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 67-115. ISBN 978-0-470-09254-5.

CLASSICOS AGENTES ANTICANCERIGENOS; AGENTE SUILANTES; ANTIMETABOLITOS; ANTIBIOTICOS ANTITUMORAIS; PRODROGAS ANTRACICLINA; SULCO DE LIGACAO DE AGENTES; INIBIDORES DA TOPOISOMERASE; INIBIDORES MITOTICOS; HORMONAIS AGENTES ANTICANCERIGENOS; REGIMES DE QUIMIOTERAPIA


76/297US=6 / Quimioterapia
Airley R. Tyrosine kinase inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 217-23. ISBN 978-0-470-09254-5.

INIBIDORES DA QUINASE DE TIROSINA; NAO-RECEPTOR INIBIDORES DE TIROSINA


77/297US=6 / Quimioterapia
Airley R. Ras inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 225-8. ISBN 978-0-470-09254-5.

INIBIDORES DE RAS


78/297US=6 / Quimioterapia
Airley R. Targeting stress proteins: HSP90 inhibitors. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 233-6. ISBN 978-0-470-09254-5.

SEGMENTACAO PROTEINAS DE ESTRESSE; INIBIDORES HSP90


79/297US=6 / Quimioterapia
Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5.

INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA


80/297US=22 / Urologia
Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2.

INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB


Primeira | Anterior | Próxima | Última